STOCKSCOUTER

StockScouter Premium

StockScouter Screener and Portfolios are now in our premium offering.
Learn more or Get it now! Stockscouter Portfolio performance

CGIX CANCER GENETICS StockScouter® Report

2

StockScouter® Score

CANCER GENETICS, a company in the sector, is expected to underperform the market over the next six months with higher than average risk

10 is the best possible rating. Learn more.

Summary

Positives

  • The enterprise value-to-sales ratio is lower than the average for comparably-sized companies in the StockScouter universe. Positive

 

Concerns

  • The multi-period measure of relative price change and consistency is well below average. Negative
  • The 50-day moving average for CGIX is significantly below its 200-day moving average. Negative
  • Short-term relative price momentum exhibits moderate weakness. Neutral/Negative

 

Short-term Outlook

Over the next 1-2 months, StockScouter forecasts that stocks will be , stocks will be , and stocks will be .

Expected Risk/Return

Progress: 100% done.
Progress: 20% done.
Low
High

Core Model Grades

N/A
N/A
B
F

Previous Ratings